The objective of this study was to compare the efficacy and tolerability of celecoxib, meloxicam and paracetamol in late Kashin-Beck disease. Adults (n = 168) with Kashin-Beck disease were randomised in clusters to receive six week courses of celecoxib 200 mg once daily, meloxicam 7.5 mg once daily or paracetamol 300 mg three times daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Celecoxib and meloxicam were efficacious in relieving pain and improving stiffness, but unable to improve physical function after six weeks. Paracetamol was efficacious in relieving pain, but unable to improve morning stiffness and physical function after six weeks. Celecoxib and meloxicam provide predictable and sustained relief from pain and stiffness. Paracetamol can relieve the pain. None of the treatments improved impaired physical function in Kashin-Beck disease.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Yang C, Niu C, Bodo M, Gabriel E, Notbohm H, Wolf E, Müller PK (1993) Fulvic acid supplementation and selenium deficiency disturb the structural integrity of mouse skeletal tissue. An animal model to study the molecular defects of Kashin-Beck disease. Biochem J 289(Pt 3):829–835
Wang Y, Yang Z, Gilula LA, Zhu C (1996) Kashin-Beck disease: radiographic appearance in the hands and wrists. Radiology 201:265–270
Chasseur C, Suetens C, Nolard N, Begaux F, Haubruge E (1997) Fungal contamination in barley and Kashin-Beck disease in Tibet. Lancet 350:1074
Haubruge E, Chasseur C, Debouck C, Begaux F, Suetens C, Mathieu F, Michel V, Gaspar C, Rooze M, Hinsenkamp M, Gillet P, Nolard N, Lognay G (2001) The prevalence of mycotoxins in Kashin-Beck disease. Int Orthop 25:159–161
Moreno-Reyes R, Suetens C, Mathieu F, Begaux F, Zhu D, Rivera MT, Boelaert M, Nève J, Perlmutter N, Vanderpas J (1998) Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status. N Engl J Med 339:1112–1120
Moreno-Reyes R, Mathieu F, Boelaert M, Begaux F, Suetens C, Rivera MT, Nève J, Perlmutter N, Vanderpas J (2003) Selenium and iodine supplementation of rural Tibetan children affected by Kashin-Beck osteoarthropathy. Am J Clin Nutr 78:137–144
La Grange M, Mathieu F, Begaux F, Suetens C, Durand MC (2001) Kashin-Beck disease and drinking water in Central Tibet. Int Orthop 25:167–169
Zhai SS, Kimbrough RD, Meng B, Han JY, LeVois M, Hou X, Yin XN (1990) Kashin-Beck disease: a cross-sectional study in seven villages in the People’s Republic of China. J Toxicol Environ Health 30:239–259
Moerman J, Uyttendaele D, Van den Broecke W, Claessens H (1992) Kashin-Beck’s disease. Acta Orthop Belg 58:227–230
Mathieu F, Begaux F, Lan ZY, Suetens C, Hinsenkamp M (1997) Clinical manifestations of Kashin-Beck disease in Nyemo Valley, Tibet. Int Orthop 21:151–156
Hinsenkamp M, Ryppens F, Begaux F, Mathieu F, De Maertelaer V, Lepeire M, Haubruge E, Chasseur C, Stallenberg B (2001) The anatomical distribution of radiological abnormalities in Kashin-Beck disease in Tibet. Int Orthop 25:142–146
Hinsenkamp M, Mathieu F, Claus W, Collard JF, de Maertelaer V (2009) Effects of physical environment on the evolution of Kashin-Beck disease in Tibet. Int Orthop 33:1085–1088
Liu FD, Wang ZL, Hinsenkamp M (1998) Osteotomy at the knee for advanced cases of Kashin-Beck disease. Int Orthop 22:87–91
Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840
Mathieu F, Suetens C, Begaux F, De Maertelaer V, Hinsenkamp M (2001) Effects of physical therapy on patients with Kashin-Beck disease in Tibet. Int Orthop 25:191–193
FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433–442
Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS (1999) Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 74:1095–1105
Williams GW, Ettlinger RE, Ruderman EM, Hubbard RC, Lonien ME, Yu SS, Zhao W, Geis GS (2000) Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J Clin Rheumatol 6:65–74
McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS (2001) Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 30:11–18
Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C (1997) Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 48:623–631
Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G (1998) Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res 47:270–276
Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 38:1535–1540
Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 38:1541–1546
Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR (1990) The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881–1884
Salzman C (1995) Medication compliance in the elderly. J Clin Psychiatry 56(Suppl 1):18–22, discussion 23
Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, Isakson PC, Geis GS (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 41:1591–1602
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284:1247–1255
Deeks JJ, Smith LA, Bradley MD (2002) Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325:619
Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325:624
The authors gratefully acknowledge the contribution made by Bing Li (secretary).
The authors declare that they have no competing interests.
This study was partially supported by a grant from NSFC (Natural Science support project Item of China) 2007BA125B04 to Dr. Fuxing Pei ChiCTR-TCR-000000395.
In the Medical College of Sichuan University, West China Hospital: Gang Liu, Luo Rui, Wei Liu, Yongtao Cheng, Dan Hu, Jiangang Wang, Li Li, Xin Ma, (rheumatologist), Fuxing Pei, Zongke Zhou, Jian Li, Bin Shen, Pengde Kang (orthopaedist); in the North Sichuan Medical College: JianPing Liu (rheumatologist); in the People’s Hospital of Sichuan province: JIanxin Zhu, Liuyi Tang, Chongxin Huang (orthopaedist); in the Chengdu Medical University of Chinese Medicine: Qun Gao (orthopaedist).
About this article
Cite this article
Luo, R., Liu, G., Liu, W. et al. Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck Disease (KBD) patients. International Orthopaedics (SICOT) 35, 1409–1414 (2011). https://doi.org/10.1007/s00264-010-1062-0